EUVIMEDEUVIMED entdecken
Fallbericht

A novel homozygous missense variant identified in the myosin VIIA motor domain of a Moroccan patient with usher syndrome

Maryem Ouarhache, Oussama Kettani, Khawla El Fizazi, Laila Bouguenouch, Karim Ouldim

Molecular Biology Reports · 2024

DOI: 10.1007/s11033-024-09603-5 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Molecular Biology Reports, 2024. Verfasst von Maryem Ouarhache und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Pharmacy and Dentistry, Biomedical and Translational Research Laboratory, Sidi Mohammed Ben Abdellah University, Fez, Morocco. m…. Hauptthemen laut MEDLINE: Usher Syndromes, Myosin VIIa, Mutation, Missense, Homozygote. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Usher syndrome 1 (USH1) is the most severe subtype of Usher syndrome characterized by severe sensorineural hearing impairment, retinitis pigmentosa, and vestibular areflexia. USH1 is usually induced by variants in MYO7A, a gene that encodes the myosin-VIIa protein. Myosin-VIIA is effectively involved in intracellular molecular traffic essential for the proper function of the cochlea, the retinal photoreceptors, and the retinal pigmented epithelial cells. METHODS AND RESULTS: In this study, we report a new homozygous missense variant (NM_000260.4: c.1657 C > T p.(His553Tyr)) in MYO7A of a 28-year-old female with symptoms consistent with USH1. This variant, c.1657 C > T p.(His553Tyr) is positioned in the highly conserved myosin-VIIA motor domain. Previous studies showed that variants in this domain might disrupt the ability of the protein to bind to actin and thus cause the disorder. CONCLUSIONS: Our findings contribute to our understanding of the phenotypic and mutational spectrum of USH1 associated with autosomal recessive MYO7A variants and emphasize the important role of molecular testing in accurately diagnosing this syndrome. More advanced research is required to understand the functional effect of the identified variant and the genotype-phonotype correlations of MYO7A-related Usher syndrome 1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Usher SyndromesMyosin VIIaMutation, MissenseHomozygoteHumansFemaleAdultMyosinsPedigree

Stichwörter der Autor:innen

MYO7AExome sequencingSanger sequencingUsher syndrome 1

Substanzen

Myosin VIIaMYO7A protein, humanMyosins

Autor:innen und Institutionen

  • Faculty of Medicine, Pharmacy and Dentistry, Biomedical and Translational Research Laboratory, Sidi Mohammed Ben Abdellah University, Fez, Morocco. maryem.ouarhache@usmba.ac.ma.
  • Medical Genetics and Oncogenetics Unit, University Hospital Center Hassan II, Fez, Morocco. maryem.ouarhache@usmba.ac.ma.
  • Medical Genetics and Oncogenetics Department, University Hospital Center Mohammed VI, Tangier, Morocco.
  • Medical Genetics and Oncogenetics Unit, University Hospital Center Hassan II, Fez, Morocco.
  • Faculty of Medicine, Pharmacy and Dentistry, Biomedical and Translational Research Laboratory, Sidi Mohammed Ben Abdellah University, Fez, Morocco.

Zitieren

APA

Ouarhache, M., Kettani, O., Fizazi, K. E., Bouguenouch, L., & Ouldim, K. (2024). A novel homozygous missense variant identified in the myosin VIIA motor domain of a Moroccan patient with usher syndrome. Molecular Biology Reports. https://doi.org/10.1007/s11033-024-09603-5

Vancouver

Ouarhache M, Kettani O, Fizazi KE, Bouguenouch L, Ouldim K. A novel homozygous missense variant identified in the myosin VIIA motor domain of a Moroccan patient with usher syndrome. Molecular Biology Reports. 2024. doi:10.1007/s11033-024-09603-5

BibTeX
@article{Ouarhache2024,
  author = {Ouarhache, Maryem and Kettani, Oussama and Fizazi, Khawla El and Bouguenouch, Laila and Ouldim, Karim},
  title = {A novel homozygous missense variant identified in the myosin VIIA motor domain of a Moroccan patient with usher syndrome},
  journal = {Molecular Biology Reports},
  year = {2024},
  doi = {10.1007/s11033-024-09603-5}
}
Kostenlos starten →